Lupin (500257) Q1 26/27 earnings summary

Executive summary

• Achieved strong revenue growth in Q1 FY27, with consolidated sales reaching ₹82,768.9 million, up 33% year-over-year, and robust EBITDA margin of 30%.

• Net income rose 16% year-over-year to ₹14,169.8 million, maintaining a healthy margin of 17.2%.

• Growth was broad-based across geographies, with North America and India leading, and significant product launches and regulatory approvals.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board on August 6, 2026.

• The review by statutory auditors found no material misstatements in the financial disclosures.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was ₹82,768.9 million, up from ₹62,683.4 million in Q1 FY26, a 33% increase year-over-year.

• EBITDA grew 50% year-over-year to ₹24,635 million, with margin improving to 30%.

• Net income reached ₹14,169.8 million, up 16% year-over-year.

• Gross profit margin improved to 74.6% from 71.3% year-over-year.

• Basic EPS (consolidated, before exceptional items) for Q1 FY27 was ₹30.95, up from ₹26.70 in Q1 FY26.

Outlook and guidance

• Plans to launch 20+ products in India and 15+ ANDAs in the US in FY27.

• Targeting 5+ biosimilar launches in the US by FY31 and 100+ new product launches globally.

• Continued focus on complex generics, biosimilars, and specialty products to drive future growth.

• The company continues to monitor the impact of new labor codes and ongoing legal matters, with provisions and settlements accounted for as required.